Among the 67 of 69 COMET patients assessed for anti–IFN-α2 autoantibodies, 4 of 19 (21%) of the critical COVID-19 cases, none of the moderate to severe cases, and none of the COVID-19− cases were positive for anti–IFN-α2 antibodies (Fig. 1A). The gene discussed is IFNA2; the disease is COVID-19.